TrkA expression in peripheral neuroblastic tumors: Prognostic significance and biological relevance

Cancer

Volumn 101, Issue 8, 2004, Pages 1873-1881

  Shimada, Hiroyuki ^a,e   Nakagawa, Atsuko ^a,b   Peters, Julius ^a   Wang, Hong ^a   Wakamatsu, Peter K ^a   Lukens, John N ^c   Matthay, Katherine K ^d   Siegel, Stuart E ^a   Seeger, Robert C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Clinical stage; Histopathology; International Neuroblastoma Pathology Classification; MYCN; Peripheral neuroblastic tumors; Prognosis; Quantitative polymerase chain reaction; trkA

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR; PROTEIN C MYB; PROTEIN TYROSINE KINASE A; UNCLASSIFIED DRUG;

AGE; ARTICLE; CANCER STAGING; CHILD; DEATH; GANGLIONEUROMA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS INDEX; NEUROBLASTOMA; ONCOGENE C MYB; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

CELL DIFFERENTIATION; CHILD, PRESCHOOL; FEMALE; GANGLIONEUROBLASTOMA; GANGLIONEUROMA; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 4744352829     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20557     Document Type: Article

References (37)

1. Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trail groups. Cancer. 1996;77:201-207.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Rev Cancer. 2003;3:203-216.
3. Maris JM, Mattahy KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264-2279.
4. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278-292.
5. Brodeur GM. TrkA expression in neuroblastomas: a new prognostic marker with biological and clinical significance. J Natl Cancer Inst. 1993;85:344-345.
6. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847-854.
7. Gilbert F, Feder M, Balaban G, et al. Human neuroblastomas and abnormalities of chromosome 1 and 17. Cancer Res. 1984;44:5444-5449.
8. Caron H, van Slius P, de Kraker J, et al. Alleic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225-230.
9. Bown N, Cotterill SJ, Lastowska M, et al. Gain of chromosome arm17q as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954-1961.
10. Hiyama E, Hiyama K, Yokoyama T, Matuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1995;1:249-255.
11. Borrello MG, Bongarzone I, Pierotti MA, et al. TRK and RET proto-oncogene expression in human neuroblastoma specimens: high frequency of TRK expression in non-advanced stages. Int J Cancer. 1993;54:540-545.
12. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 1993;53:2044-2050.
13. Miyake M, Suzuki T, Shimada H, Stram D, Seeger RC. High affinity nerve growth factor receptor expression (gp140 trkA), N-myc amplification, histopathology, and survival in neuroblastoma. Progr Clin Biol Res. 1994;385:163-168.
14. Kramer K, Cheung NK, Gerald WL, et al. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer. 1997;33:2098-2100.
15. Combaret V, Gross N, Lasset C, et al. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br J Cancer. 1997;75:1151-1155.
16. Eggert A, Ho R, Ikegaki N, Liu XG, Brodeur GM. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification. Med Pediatr Oncol. 2000;35:623-627.
17. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell. 1998;11:115-124.
18. Shimada H, Stram D, Chatten J, et al. Identification of subsets of neuroblastomas: combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995;87:1470-1476.
19. Goto S, Umehara S, Gerbing RB, et al. Histopathology and MYCN status in peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001;92:2699-2708.
20. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer. 1971;27:374-378.
21. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:18-26.
22. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
23. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256-1264.
24. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with Stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260-1268.
25. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991;324:219-226.
26. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Raold B. Terminology and morphologic criteria of neuroblastic tumors: recommendation by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349-363.
27. Shimada H, Ambros IA, Dehner LP, et al. Establishment of the International Neuroblastoma Pathology Classification (Shimada System). Cancer. 1999;86:364-372.
28. Shimada H, Umehara S, Monobe Y, et al. International Neuroblastoma Pathology Classification (the Shimada System) for prognostic evaluation of peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001;92:2451-2561.
29. Chomczynski P, Sacchi N. A single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
30. Pradhan SM, Ge S, Kuroda C, Peters J, Niesen CE. Quantitative fluorescent RT PCR measurements of postnatal calcium channel gene expression in rat hippocampal subfields. Ann NY Acad Sci. 1999;868:228-232.
31. Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM. Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem. 1993;268:15150-15157.
32. Celi FS, Zenilman ME, Shuldiner AR. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res. 1993;21:1047.
33. Cox DR. Regression model and life-tables. J R Stat Soc B. 1972;34,187-220.
34. Schmidt ML, Salwen HR, Chagnovich D, Bauer KD, Crawford SE, Cohn SL. Evidence for molecular heterogeneity in human ganglioneuroblastoma. Pediatr Pathol. 1993:13:787-796.
35. Eggert A, Ikegaki N, Liu XG, Chou TT, Brodeur GM. TrkA signal transduction pathways in neuroblastoma. Med Pediatr Oncol. 2001;36:108-110.
36. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992;52:1634-1638.
37. Nakagawara A, Brodeur GM. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer. 1997;33:2050-2053.